|
Name |
Guignardone J
|
Molecular Formula | C17H24O5 | |
IUPAC Name* |
(1R,3aR,5S,7R,9aS)-5,7-dihydroxy-7-(hydroxymethyl)-3a-methyl-1-prop-1-en-2-yl-2,3,5,6,9,9a-hexahydro-1H-cyclopenta[b]chromen-8-one
|
|
SMILES |
CC(=C)[C@@H]1CC[C@@]2([C@H]1CC3=C(O2)[C@H](C[C@](C3=O)(CO)O)O)C
|
|
InChI |
InChI=1S/C17H24O5/c1-9(2)10-4-5-16(3)12(10)6-11-14(22-16)13(19)7-17(21,8-18)15(11)20/h10,12-13,18-19,21H,1,4-8H2,2-3H3/t10-,12-,13-,16+,17+/m0/s1
|
|
InChIKey |
NDRMXJQIHGDADJ-AWKHGQQRSA-N
|
|
Synonyms |
Guignardone J; CHEMBL3752333; HY-N10299; CS-0373695
|
|
CAS | NA | |
PubChem CID | 127037621 | |
ChEMBL ID | CHEMBL3752333 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 308.4 | ALogp: | 1.2 |
HBD: | 3 | HBA: | 5 |
Rotatable Bonds: | 2 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 87.0 | Aromatic Rings: | 3 |
Heavy Atoms: | 22 | QED Weighted: | 0.673 |
Caco-2 Permeability: | -4.838 | MDCK Permeability: | 0.00000933 |
Pgp-inhibitor: | 0.001 | Pgp-substrate: | 0.137 |
Human Intestinal Absorption (HIA): | 0.192 | 20% Bioavailability (F20%): | 0.897 |
30% Bioavailability (F30%): | 0.005 |
Blood-Brain-Barrier Penetration (BBB): | 0.703 | Plasma Protein Binding (PPB): | 55.14% |
Volume Distribution (VD): | 1.075 | Fu: | 52.02% |
CYP1A2-inhibitor: | 0.015 | CYP1A2-substrate: | 0.739 |
CYP2C19-inhibitor: | 0.019 | CYP2C19-substrate: | 0.813 |
CYP2C9-inhibitor: | 0.009 | CYP2C9-substrate: | 0.09 |
CYP2D6-inhibitor: | 0.002 | CYP2D6-substrate: | 0.189 |
CYP3A4-inhibitor: | 0.057 | CYP3A4-substrate: | 0.352 |
Clearance (CL): | 7.255 | Half-life (T1/2): | 0.68 |
hERG Blockers: | 0.014 | Human Hepatotoxicity (H-HT): | 0.37 |
Drug-inuced Liver Injury (DILI): | 0.833 | AMES Toxicity: | 0.032 |
Rat Oral Acute Toxicity: | 0.885 | Maximum Recommended Daily Dose: | 0.35 |
Skin Sensitization: | 0.069 | Carcinogencity: | 0.731 |
Eye Corrosion: | 0.021 | Eye Irritation: | 0.335 |
Respiratory Toxicity: | 0.054 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003338 | 0.690 | D04VIS | 0.296 | ||||
ENC003594 | 0.638 | D0KR5B | 0.275 | ||||
ENC002719 | 0.625 | D0D1SG | 0.275 | ||||
ENC003339 | 0.589 | D0R7JT | 0.269 | ||||
ENC003343 | 0.589 | D08PIQ | 0.269 | ||||
ENC002721 | 0.539 | D0V9DZ | 0.269 | ||||
ENC006127 | 0.519 | D0C7JF | 0.260 | ||||
ENC003341 | 0.506 | D03BLF | 0.252 | ||||
ENC003340 | 0.469 | D07DVK | 0.252 | ||||
ENC006126 | 0.462 | D0CW1P | 0.252 |